Alogliptin-Pioglitazone and Insulin Regimen for Inpatient Glycemic Control: A Randomized Continuous Glucose Monitoring Pilot Trial
AACE Endocrinology and Diabetes · 2026-09 · 13 (5) · 762-769
DOI: 10.1016/j.aed.2026.06.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift AACE Endocrinology and Diabetes, 2026-09. Verfasst von Parson Camuto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FAPESP, CNPq.
Abstract (Originalsprache)
Objectives
Hospitalized patients with type 2 diabetes (T2D) frequently develop hyperglycemia, hypoglycemia, and glycemic variability, which are associated with adverse outcomes outside the intensive care unit. This pilot randomized controlled trial evaluated whether adding a fixed-dose combination (FDC) of alogliptin/pioglitazone to standard basal-bolus insulin improved time in range (TIR), reduced hypoglycemia and/or bolus insulin requirements versus placebo, while generating effect size estimates for a future multicenter trial.
Methods
In this randomized, double-blind, placebo-controlled pilot study, the placebo group (n = 12) received basal-bolus insulin (neutral protamine Hagedorn plus regular insulin) with placebo, whereas the intervention group (IG) (n = 18) received the same insulin regimen plus daily alogliptin/pioglitazone FDC (25/15 mg). Continuous glucose monitoring (FreeStyle Libre 2) assessed TIR (70-180 mg/dL) as the primary endpoint, together with time above range and time below range, during a prespecified 4-d postrandomisation analysis period.
Results
The IG achieved significantly higher TIR than placebo (72.44% vs 38.58%; P 250 mg/dL (2.94% vs 28.16%; P 0.05). By day 4, the IG required significantly lower daily bolus insulin doses (P = 0.0003).
Conclusions
In this highly selected inpatient population, adjunctive alogliptin/pioglitazone added to basal-bolus insulin improved continuous glucose monitoring-derived glycaemic stability. Larger adequately powered multicentre trials are needed to confirm safety and efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Förderung
- FAPESP
- CNPq
Zitieren
APA
Camuto, P., Guadagnini, D., Assalin, H. B., Magro, D. O., Santos, A., & Saad, M. J. (2026). Alogliptin-Pioglitazone and Insulin Regimen for Inpatient Glycemic Control: A Randomized Continuous Glucose Monitoring Pilot Trial. AACE Endocrinology and Diabetes, 13(5), 762-769. https://doi.org/10.1016/j.aed.2026.06.010
Vancouver
Camuto P, Guadagnini D, Assalin HB, Magro DO, Santos A, Saad MJ. Alogliptin-Pioglitazone and Insulin Regimen for Inpatient Glycemic Control: A Randomized Continuous Glucose Monitoring Pilot Trial. AACE Endocrinology and Diabetes. 2026;13(5):762-769. doi:10.1016/j.aed.2026.06.010
BibTeX
@article{Camuto2026,
author = {Camuto, Parson and Guadagnini, Dioze and Assalin, Heloisa B and Magro, Daniela O and Santos, Andrey and Saad, Mario Ja},
title = {Alogliptin-Pioglitazone and Insulin Regimen for Inpatient Glycemic Control: A Randomized Continuous Glucose Monitoring Pilot Trial},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {5},
pages = {762--769},
doi = {10.1016/j.aed.2026.06.010}
}
EUVIMED